**Infant radiant warmer**

**Country of origin** | India

---

**Health problem addressed**

In under-resourced settings, hypothermia at birth is one of the most important risk factors for newborn morbidity and mortality. 99% of newborns that die globally are in such settings. It is vital to keep newborns warm and help them achieve thermoregulation in order to prevent and minimize morbidities and mortalities due to hypothermia.

---

**Product description**

The device consists of a biocompatible bed on which to place the infant, and an overhead heater that delivers radiant heat. A skin temperature probe monitors infant temperature. Heat output can be controlled manually or through baby mode (feedback mode) for thermoregulation. Visual and audio alarms are present for safety. An APGAR timer helps to efficiently take APGAR scores post-delivery.

---

**Developer's claims of products benefits**

Current radiant warmers have heaters typically made from quartz or ceramic. These heaters tend to breakdown faster as well as take a much longer time to heat up – up to 13 minutes in some cases. Each additional minute of cold stress can lead to increased morbidity for an infant. This device gives better clinical results because it provides uniform heating across the bed as well as a much faster warmup time (4 minutes only) that reduces the time to warm a hypothermic infant. Furthermore, the lower power consumption and long life of the heating element (Calrod heater) lead to considerable cost savings.

---

**Suitability for low-resource settings**

The device uses less power at startup and during operation compared to other radiant warmers. It is designed for infection control (e.g. non-stitch biocompatible mattress for no infections in stitches plus no need for a mattress cover). It has a faster warmup time for high volume environments with little pre-warming. Over 1500 warmers have been deployed in low-resource settings.

The device has been designed, developed and manufactured in India based on extensive customer input in India and similar countries. It has been adopted in Tier 2 and 3 towns in India, as well throughout the country of Myanmar by the Ministry of Health. Testing of the device includes protocols that try to simulate low-resource setting issues such as voltage fluctuations, high humidity etc.

---

**Operating steps**

The device is usually pre-warmed in manual mode for at least four minutes. The infant is then placed on the bed mattress and the skin temperature probe is attached. The operator then switches to baby mode (feedback) and enters the desired baby temperature. The APGAR timer and observation light can be switched on as needed.

---

**Regulatory status**

It conforms with the requirements of Medical Devices Directive 93/42/EEC - BSI CE 0086 mark. It is also certified ISO 13485. It has US FDA 510K clearance (K121625), and it is ROHS compliant.

---

**Use and maintenance**

**User:** Physician, nurse, midwife  
**Training:** Initial training by manufacturer, and operator manual  
**Maintenance:** Annually by technician, engineer, or manufacturer

---

**Environment of use**

**Settings:** Rural, urban settings, primary (health post, health center), secondary (general hospital), tertiary (specialized hospital)  
**Requirements:** Continuous power supply (100-240V). Can withstand some fluctuations in voltage and occasional spikes, but stable power supply is strongly recommended. General cleaning supplies to disinfect after every infant are needed.

---

**Product specifications**

| Dimensions (mm): 1120 x 655 x 1800 (minimum height) | List price (USD): 3500 |
| Weight (kg): 72 | Other features: Software use, mobile, capital equipment |
| Consumables: Reflector patches to cover the sensor are recommended in order to provide an accurate reading | Year of commercialization: 2009 |
| Life time: 7 years | Currently sold in: 115 countries. Emerging market countries include Albania, Algeria, Brazil, Bulgaria, Cambodia, Chile, Dominican Republic, Egypt, Gabon, India, Indonesia, Iraq, Jordan, Kazakhstan, Kenya, Lebanon, Macedonia, Nigeria, Palestinian Territory, Philippines, Syria, South Africa, Vietnam. |
| Shelf life: 2 years (6 months without any operation) | |
| Retail Price (USD): 3000, with considerable variation between countries | |

---

Contact details  
Ashish Gupta  
Email lowresourcesetting@gmail.com  
Telephone +91 80 408 85941  
Web http://bit.ly/QdK0Ss  
http://www.who.int/medical_devices
Disclaimer

Eligibility for inclusion in the compendium has been evaluated by WHO and external technical advisers listed in the Acknowledgements. However, the evaluation has been solely based on a limited assessment of data and information submitted in the developers’ applications and, where available, of additional sources of evidence, such as literature search results or other publicly available information. There has been no rigorous review for safety, efficacy, quality, applicability, nor cost acceptability of any of the technologies. Therefore, inclusion in the compendium does not constitute a warranty of the fitness of any technology for a particular purpose. Besides, the responsibility for the quality, safety and efficacy of each technology remains with the developer and/or manufacturer. The decision to include a particular technology in the compendium is subject to change on the basis of new information that may subsequently become available to WHO.

WHO will not be held to endorse nor to recommend any technology included in the compendium. Inclusion in the compendium solely aims at drawing stakeholders’ attention to innovative health technologies, either existing or under development, with a view to fostering the development and availability of, and/or access to, new and emerging technologies which are likely to be accessible, appropriate and affordable for use in low- and middle-income countries.

WHO does not furthermore warrant or represent that:

1. the list of innovative health technologies is exhaustive or error free; and/or that
2. the technologies which are included in the compendium will be embodied in future editions of the compendium; and/or that
3. the use of the technologies listed is, or will be, in accordance with the national laws and regulations of any country, including but not limited to patent laws; and/or that
4. any product that may be developed from the listed technologies will be successfully commercialized in target countries or that WHO will finance or otherwise support the development or commercialization of any such product.

WHO disclaims any and all liability and responsibility whatsoever for any injury, death, loss, damage, use of personal data, or other prejudice of any kind whatsoever that may arise as a result of, or in connection with, the procurement, distribution and/or use of any technology embodied in the compendium, or of any resulting product and any future development thereof.

Developers whose technology has been included in the compendium shall not, in any statement of an advertising, commercial and/or promotional nature, refer to their participation and/or inclusion in the compendium. In no case shall the latter use the WHO name and/or the emblem, or any abbreviation thereof, in relation to their business or otherwise.